James Lusk, SLP in Atkins, AR - Speech-Language Pathologist

James Lusk, SLP is a Speech-language Pathologist based in Atkins, Arkansas. James Lusk is licensed to practice in * (Not Available) (license number ) and his current practice location is 408 N Church St, Atkins, Arkansas. He can be reached at his office (for appointments etc.) via phone at (479) 495-0651.

NPI number for James Lusk is 1831797802 and his current mailing address is Po Box 217, Russellville, Arkansas. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1831797802.

Contact Information

	James Lusk, SLP
	408 N Church St, Atkins, AR 72823-4149
	(479) 495-0651
	Not Available

Healthcare Provider's Profile

Full Name	James Lusk
Gender	Male
Speciality	Speech-language Pathologist
Location	408 N Church St, Atkins, Arkansas
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1831797802
Provider Enumeration Date: 10/13/2020
Last Update Date: 10/13/2020

Medical Identifiers

Medical identifiers for James Lusk such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1831797802	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. James Lusk is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
James Lusk, SLP Po Box 217, Russellville, AR 72811-0217 Ph: () -	James Lusk, SLP 408 N Church St, Atkins, AR 72823-4149 Ph: (479) 495-0651

News Archive

COVID-19 Prevention Network announces Phase 3 trials to evaluate monoclonal antibodies

The COVID-19 Prevention Network (CoVPN) today announced two Phase 3 trials to determine whether monoclonal antibodies (mAbs) can prevent SARS-CoV-2, the virus that causes COVID-19.

Northwestern University move closer to new therapies for neurodegenerative disease

French neurologist Jean-Martin Charcot first described amyotrophic lateral sclerosis (ALS) in 1869, but, nearly 140 years later, little is known about the cause of the devastating neurodegenerative disease, and there is no cure.

Study identifies genetic mutation associated with rare blood vessel disease

Understanding of fibromuscular dysplasia (FMD), a rare blood vessel disease, is making the jump from the laboratory to the clinic with new findings about a genetic variant.

New paper discusses potential of tumor-derived microvesicles

A new paper by Crislyn D'Souza-Schorey, professor of biological sciences at the University of Notre Dame, discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles are membrane-bound sacs released by tumor cells and can be detected in the body fluids of cancer patients.

James Lusk, SLP - Speech-Language Pathologist in Atkins, AR